Sakar Healthcare shares surged 8.28% to ₹754.40 following the announcement of a significant bulk deal transaction. According to bulk deal data on the NSE, Stellar Wealth Partners India Fund I LP acquired 1.95 lakh shares, representing a 0.88% equity stake at an average price of ₹664.58 per share on 15 May 2026.
The investment represents a fresh stake entry in the current quarter, as Gautam Baid or Stellar Wealth Partners India Fund I LP did not feature in Sakar Healthcare's shareholding pattern for the quarter ended 31 March 2026. Stellar Wealth Partners India Fund I LP is a Delaware-based investment partnership founded by investor Gautam Baid.
Ahmedabad-based Sakar Healthcare is a pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products.
On a consolidated basis, Sakar Healthcare's net profit surged 91.32% to ₹11.02 crore while net sales rose 41.52% to ₹71.10 crore in Q4 March 2026 over Q4 March 2025. This robust financial performance may have contributed to investor confidence in the company's prospects.
